Structures by: Leyssens T.
Total: 125
CaCl2 etiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.968(2)Å b=12.170(4)Å c=15.304(4)Å
α=87.17(2)° β=86.30(2)° γ=74.76(2)°
CaCl2 Levetiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.93030(11)Å b=15.1768(2)Å c=23.7226(3)Å
α=90° β=90° γ=90°
C16H18O2S2
C16H18O2S2
Chemical Communications (2019)
a=5.43658(14)Å b=5.70292(17)Å c=25.1230(6)Å
α=90° β=93.371(2)° γ=90°
C16H28Cl2N4O4Zn
C16H28Cl2N4O4Zn
Chemical communications (Cambridge, England) (2018) 54, 77 10890-10892
a=17.6678(6)Å b=6.9371(2)Å c=18.0628(8)Å
α=90° β=91.515(3)° γ=90°
C16H28Cl4N4O4Zn2
C16H28Cl4N4O4Zn2
Chemical communications (Cambridge, England) (2018) 54, 77 10890-10892
a=6.3692(3)Å b=11.6771(4)Å c=17.1077(6)Å
α=90° β=98.496(4)° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph I
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.1578(5)Å b=5.8278(2)Å c=25.6828(14)Å
α=90° β=98.762(5)° γ=90°
S-naproxen L-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=16.2991(7)Å b=5.8654(3)Å c=18.6876(9)Å
α=90° β=100.052(4)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph I
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=9.9964(3)Å b=9.0958(4)Å c=39.9654(15)Å
α=90° β=90° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.5901(6)Å b=5.7587(3)Å c=51.425(3)Å
α=90° β=90° γ=90°
RS-naproxen L-proline 1:1 cocrystal, polymorph III
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.705(2)Å b=5.7631(8)Å c=25.000(5)Å
α=90° β=95.041(11)° γ=90°
S-naproxen ethanol solvate
C14H14O3,C2H6O
CrystEngComm (2018) 20, 45 7308
a=5.9273(2)Å b=8.7713(5)Å c=28.0747(15)Å
α=90° β=90° γ=90°
1:1 RS-naproxen D-proline cocrystal methanol solvate
2(C14H14O3),2(C5H9NO2),CH4O
CrystEngComm (2018) 20, 45 7308
a=12.9532(4)Å b=5.76337(15)Å c=25.2764(6)Å
α=90° β=93.984(3)° γ=90°
S-naproxen DL-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.8836(7)Å b=9.0952(18)Å c=44.047(10)Å
α=90° β=90° γ=90°
S-naproxen DL-proline 1:1 cocrystal
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=8.84337(19)Å b=5.83510(15)Å c=33.6766(7)Å
α=90° β=91.9839(19)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph II
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=34.537(4)Å b=9.0077(8)Å c=5.7183(5)Å
α=90° β=90° γ=90°
1:1 S-naproxen DL-proline cocrystal hydrate
2(C14H14O3),2(C5H9NO2),2(H2O1)
CrystEngComm (2018) 20, 45 7308
a=6.06468(13)Å b=12.2629(3)Å c=50.6290(15)Å
α=90° β=90° γ=90°
S-naproxen L-proline 2:3 cocrystal
2(C14H14O3),3(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.70180(10)Å b=18.8609(3)Å c=37.2392(5)Å
α=90° β=90° γ=90°
S-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.88160(7)Å b=8.79809(10)Å c=45.4679(5)Å
α=90° β=90° γ=90°
C19H20NO,Cl
C19H20NO,Cl
CrystEngComm (2018) 20, 24 3318
a=8.3825(4)Å b=14.3515(8)Å c=13.3425(7)Å
α=90° β=96.835(5)° γ=90°
C19H20NO,Br
C19H20NO,Br
CrystEngComm (2018) 20, 24 3318
a=8.3080(4)Å b=13.9039(8)Å c=13.6580(6)Å
α=90° β=96.642(4)° γ=90°
C23H22NO,NO3
C23H22NO,NO3
CrystEngComm (2018) 20, 24 3318
a=14.9120(4)Å b=6.9922(2)Å c=37.2099(13)Å
α=90° β=90° γ=90°
C19H20NO,NO3
C19H20NO,NO3
CrystEngComm (2018) 20, 24 3318
a=10.4953(9)Å b=19.9612(19)Å c=8.1903(7)Å
α=90° β=90° γ=90°
C20H22NO21,Cl1,2(H2O)
C20H22NO21,Cl1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5183(3)Å b=24.4350(7)Å c=7.1002(2)Å
α=90° β=98.786(3)° γ=90°
C20H22NO2,NO3,H2O
C20H22NO2,NO3,H2O
CrystEngComm (2018) 20, 24 3318
a=10.9418(7)Å b=22.2438(13)Å c=8.0740(6)Å
α=90° β=99.632(7)° γ=90°
Tetrakis(2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium) tris(phosphoric acid) nonahydrate tetradihydrogen phosphate
2(C20H22NO2),2(H2O4P),1.5(H3O4P),4.5(H2O)
CrystEngComm (2018) 20, 24 3318
a=12.0289(5)Å b=12.4435(5)Å c=17.4047(7)Å
α=76.128(4)° β=81.814(4)° γ=79.953(4)°
C23H22NO1,Cl1
C23H22NO1,Cl1
CrystEngComm (2018) 20, 24 3318
a=17.6960(6)Å b=15.1030(4)Å c=6.9665(3)Å
α=90° β=92.410(4)° γ=90°
C19H21BrNO1.50
C19H21BrNO1.50
CrystEngComm (2018) 20, 24 3318
a=12.8779(5)Å b=10.4911(5)Å c=12.8498(7)Å
α=90° β=94.836(4)° γ=90°
2-[(E)-2-(2-hydroxy-5-nitrophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium hydrogen sulfate
C19H19N2O3,HO4S
CrystEngComm (2018) 20, 24 3318
a=11.768(3)Å b=25.295(5)Å c=7.006(2)Å
α=90° β=104.70(3)° γ=90°
C19H19N2O3,NO3
C19H19N2O3,NO3
CrystEngComm (2018) 20, 24 3318
a=7.227(3)Å b=10.0542(10)Å c=12.687(3)Å
α=80.825(14)° β=89.00(2)° γ=88.089(18)°
C19H17N3O5
C19H17N3O5
CrystEngComm (2018) 20, 24 3318
a=18.8741(12)Å b=6.2632(3)Å c=14.2571(7)Å
α=90° β=98.548(6)° γ=90°
C23H22NO,Br
C23H22NO,Br
CrystEngComm (2018) 20, 24 3318
a=17.8583(18)Å b=15.1686(10)Å c=6.9757(3)Å
α=90° β=93.704(7)° γ=90°
C20H22NO2,HO4S
C20H22NO2,HO4S
CrystEngComm (2018) 20, 24 3318
a=7.8327(5)Å b=16.0190(13)Å c=15.1017(19)Å
α=90° β=90° γ=90°
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
CrystEngComm (2018) 20, 24 3318
a=12.6562(3)Å b=13.9654(7)Å c=28.3803(12)Å
α=83.572(4)° β=79.127(3)° γ=78.777(3)°
C38H38Br4N2O2Zn2
C38H38Br4N2O2Zn2
CrystEngComm (2019) 21, 33 4925
a=9.3000(8)Å b=9.3023(8)Å c=11.3137(10)Å
α=94.166(7)° β=108.407(8)° γ=96.344(7)°
C19H18Cl2N2O3Zn
C19H18Cl2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.659(4)Å b=15.216(3)Å c=6.9834(12)Å
α=90° β=94.06(2)° γ=90°
C19H20NO,Cl3H2OZn
C19H20NO,Cl3H2OZn
CrystEngComm (2019) 21, 33 4925
a=8.2890(5)Å b=21.5395(16)Å c=12.2257(11)Å
α=90° β=97.748(7)° γ=90°
C19H18Cl3N2O3Zn,C19H19N2O3
C19H18Cl3N2O3Zn,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8909(7)Å b=12.6582(7)Å c=25.0471(16)Å
α=90° β=98.073(6)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=12.388(6)Å b=13.671(7)Å c=14.855(8)Å
α=108.02(5)° β=101.20(4)° γ=101.01(4)°
Zinc(2+) ion 2-[(E)-2-(3-methoxy-2-oxidophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium ethanol dibromide
C20H20NO2,Zn2,2(Br1),C2H6O1
CrystEngComm (2019) 21, 33 4925
a=10.1512(3)Å b=12.0717(4)Å c=21.8754(7)Å
α=84.876(3)° β=77.406(2)° γ=65.333(3)°
Zinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(5-nitro-2-oxidophenyl)ethenyl]-3H-indol-1-ium) dichloride
2(C19H18N2O3),Zn2,2Cl1
CrystEngComm (2019) 21, 33 4925
a=8.86510(16)Å b=14.8667(4)Å c=15.2523(5)Å
α=113.831(3)° β=94.587(2)° γ=91.7161(19)°
Dizinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(2-oxidonaphthalen-1-yl)ethenyl]-3H-indol-1-ium) tetrabromide acetone solvate
C46H42Br4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.97440(14)Å b=12.9849(2)Å c=20.5608(3)Å
α=90° β=91.4476(14)° γ=90°
2(C22H27Cl2NO3Zn),H2O
2(C22H27Cl2NO3Zn),H2O
CrystEngComm (2019) 21, 33 4925
a=21.9384(11)Å b=9.7692(4)Å c=21.2029(10)Å
α=90° β=97.634(5)° γ=90°
C19H18Br2N2O3Zn
C19H18Br2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.517(7)Å b=15.290(4)Å c=7.252(2)Å
α=90° β=92.47(3)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=6.5663(8)Å b=15.8090(12)Å c=20.1333(15)Å
α=90° β=90° γ=90°
2(C21H21Br2N3O3Zn),C2H3N
2(C21H21Br2N3O3Zn),C2H3N
CrystEngComm (2019) 21, 33 4925
a=14.4022(7)Å b=13.0338(6)Å c=26.6165(16)Å
α=90° β=99.770(6)° γ=90°
2(C19H19N2O3),Cl4Co,H2O
2(C19H19N2O3),Cl4Co,H2O
CrystEngComm (2019) 21, 33 4925
a=11.6156(11)Å b=13.0124(6)Å c=14.0058(14)Å
α=77.862(6)° β=76.661(8)° γ=87.030(6)°
C38H36Br2N4O6Zn
C38H36Br2N4O6Zn
CrystEngComm (2019) 21, 33 4925
a=9.1737(6)Å b=14.9690(14)Å c=15.421(2)Å
α=116.717(11)° β=98.405(8)° γ=89.487(7)°
C19H18Cl3CoN2O3,C19H19N2O3
C19H18Cl3CoN2O3,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.9195(9)Å b=12.6137(7)Å c=25.1143(14)Å
α=90° β=97.136(6)° γ=90°
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8302(4)Å b=12.7363(3)Å c=24.6870(9)Å
α=90° β=98.600(3)° γ=90°
L-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.6999(2)Å b=6.5428(3)Å c=23.1874(10)Å
α=90.00° β=94.835(4)° γ=90.00°
D-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.7713(2)Å b=6.2520(3)Å c=23.8346(11)Å
α=90.00° β=92.047(4)° γ=90.00°
DL-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=6.1054(2)Å b=12.4750(5)Å c=49.1664(13)Å
α=90.00° β=90.00° γ=90.00°
L-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=13.122(2)Å b=5.8980(10)Å c=24.075(3)Å
α=90.00° β=95.560(5)° γ=90.00°
CaCl2 Levetiracetam Nicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=11.9243(5)Å b=8.0669(3)Å c=15.4348(7)Å
α=90° β=92.338(4)° γ=90°
RS-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.84172(9)Å b=8.98394(13)Å c=45.6816(8)Å
α=90° β=90° γ=90°
2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium dihydrate bromide
C20H22NO21,Br1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5976(3)Å b=23.9015(6)Å c=7.36093(15)Å
α=90° β=98.766(2)° γ=90°
C46H42Cl4N2O2Zn2,C3H6O
C46H42Cl4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.8991(3)Å b=13.0969(4)Å c=19.8630(6)Å
α=90° β=90.033(3)° γ=90°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.3366(4)Å b=6.9013(6)Å c=44.227(4)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
2(C8H10N4O2),C5H6O4
2(C8H10N4O2),C5H6O4
CrystEngComm (2014) 16, 41 9603
a=7.6414(6)Å b=15.7487(9)Å c=39.130(3)Å
α=90° β=90° γ=90°
2(C8H10N4O2),C6H10O4
2(C8H10N4O2),C6H10O4
CrystEngComm (2014) 16, 41 9603
a=21.3368(9)Å b=17.0520(5)Å c=6.7877(3)Å
α=90° β=93.674(4)° γ=90°
2(C8H10N4O2),C5H6O4
2(C8H10N4O2),C5H6O4
CrystEngComm (2014) 16, 41 9603
a=8.5926(3)Å b=18.4382(7)Å c=14.9164(5)Å
α=90° β=92.437(3)° γ=90°
2(C8H10N4O2),C5H6O4
2(C8H10N4O2),C5H6O4
CrystEngComm (2014) 16, 41 9603
a=7.9317(6)Å b=8.2797(2)Å c=20.4795(15)Å
α=89.975(6)° β=83.335(6)° γ=61.808(6)°
4(C8H10N4O2),2(C5H6O4),C2H3N
4(C8H10N4O2),2(C5H6O4),C2H3N
CrystEngComm (2014) 16, 41 9603
a=44.164(3)Å b=3.94516(19)Å c=27.676(3)Å
α=90° β=96.236(8)° γ=90°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.5932(3)Å b=7.8325(3)Å c=11.9547(4)Å
α=90.00° β=103.830(3)° γ=90.00°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.3020(8)Å b=11.5223(7)Å c=8.4172(5)Å
α=90.00° β=95.966(7)° γ=90.00°
C8H14N2O2,H2O
C8H14N2O2,H2O
Acta Crystallographica Section B (2013) 69, 4 371-378
a=7.2006(5)Å b=7.9639(5)Å c=9.5468(6)Å
α=85.293(5)° β=76.031(6)° γ=70.023(6)°
C20H24N8O8
C20H24N8O8
Crystal Growth & Design (2012) 12, 3 1520-1530
a=13.1974(3)Å b=6.9662(2)Å c=26.2816(8)Å
α=90° β=97.847(1)° γ=90°
C8H14N2O2,C6H10O4
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=12.9082(9)Å b=11.5417(8)Å c=12.5179(9)Å
α=90.00° β=116.342(9)° γ=90.00°
Levetiracetam 2,2-dimethylsuccinic acid cocrystal
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.23877(7)Å b=11.55362(12)Å c=11.34360(12)Å
α=90.00000° β=90.9259(9)° γ=90.00000°
Etiracetam 2,4-dihydroxybenzoic acid cocrystal
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.60584(3)Å b=13.11919(7)Å c=18.80723(8)Å
α=90.00000° β=90.00000° γ=90.00000°
C8H14N2O2,C7H5NO4
C8H14N2O2,C7H5NO4
Crystal Growth & Design (2014) 14, 6 2880
a=5.8455(2)Å b=11.6845(12)Å c=12.5762(10)Å
α=78.856(8)° β=82.443(6)° γ=84.035(7)°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=8.0511(4)Å b=13.0536(6)Å c=23.0243(9)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=24.2697(8)Å b=7.4683(2)Å c=13.3230(5)Å
α=90.00° β=104.663(4)° γ=90.00°
2(C7H5NO4),C8H14N2O2
2(C7H5NO4),C8H14N2O2
Crystal Growth & Design (2014) 14, 6 2880
a=7.0988(9)Å b=7.3613(10)Å c=12.1428(13)Å
α=77.496(10)° β=88.250(10)° γ=74.232(12)°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7253(2)Å b=20.2528(7)Å c=10.9457(5)Å
α=90.00° β=100.085(4)° γ=90.00°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7646(4)Å b=19.8963(14)Å c=11.0690(8)Å
α=90.00° β=99.331(6)° γ=90.00°
Stanozolol / malonic acid cocrystal
C21H32N2O,C3H4O4
Crystal Growth & Design (2014) 14, 7 3408
a=10.6644(7)Å b=7.2335(5)Å c=15.0947(10)Å
α=90.00° β=106.016(7)° γ=90.00°
Stanozolol / D-phenyllactic acid cocrystal
2(C21H32N2O),C9H10O3,C2H3N
Crystal Growth & Design (2014) 14, 7 3408
a=58.6098(12)Å b=7.5624(2)Å c=10.7139(4)Å
α=90.00° β=97.989(2)° γ=90.00°
Stanozolol / 6-hydroxy-2-naphthoic acid
C21H32N2O,C11H8O3
Crystal Growth & Design (2014) 14, 7 3408
a=7.9530(6)Å b=8.6403(7)Å c=10.4582(7)Å
α=83.337(6)° β=86.973(6)° γ=75.431(7)°
C21H32N2O,2(C5H8O4)
C21H32N2O,2(C5H8O4)
Crystal Growth & Design (2014) 14, 8 3996
a=7.26590(10)Å b=10.3858(3)Å c=42.1865(10)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=12.0408(8)Å b=5.9067(3)Å c=12.1169(8)Å
α=90.00° β=113.961(8)° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=5.9628(4)Å b=11.5797(8)Å c=22.5983(18)Å
α=90° β=95.615(8)° γ=90°
C13H18O2,C8H14N2O2
C13H18O2,C8H14N2O2
Crystal Growth & Design (2014) 14, 8 3996
a=7.351(2)Å b=9.780(3)Å c=29.993(5)Å
α=90.00° β=90.00° γ=90.00°
C15H13FN2O
C15H13FN2O
Crystal Growth & Design (2015) 15, 8 4005
a=20.3160(18)Å b=5.2050(3)Å c=13.5364(14)Å
α=90.00° β=114.387(12)° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=18.549(3)Å b=13.827(2)Å c=5.3162(7)Å
α=90.00° β=90.00° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2015) 15, 8 4005
a=7.0276(4)Å b=7.7445(5)Å c=25.6078(13)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=8.2225(4)Å b=5.7932(3)Å c=14.5687(6)Å
α=90.00° β=90.377(4)° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=8.6581(7)Å b=5.1375(3)Å c=15.7993(10)Å
α=90.00° β=100.982(7)° γ=90.00°
C21H18N2O
C21H18N2O
Crystal Growth & Design (2015) 15, 8 4005
a=8.3299(3)Å b=5.7214(2)Å c=17.5391(5)Å
α=90.00° β=91.143(3)° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=25.096(2)Å b=5.6957(4)Å c=20.3318(15)Å
α=90.00° β=107.199(6)° γ=90.00°
C15H13N3O3
C15H13N3O3
Crystal Growth & Design (2015) 15, 8 4005
a=7.1806(6)Å b=7.7128(7)Å c=25.267(2)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.1707(5)Å b=13.2714(12)Å c=20.434(2)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=5.2563(5)Å b=9.7698(12)Å c=26.617(3)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O2
C16H16N2O2
Crystal Growth & Design (2015) 15, 8 4005
a=5.1883(6)Å b=9.8853(10)Å c=27.403(3)Å
α=90.00° β=90.00° γ=90.00°